Literature DB >> 19682190

Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.

Huy Anh Tran1, Glenn Edward Malcolm Reeves, Robert Gibson, John Richard Attia.   

Abstract

BACKGROUND AND AIM: Thyroid dysfunction is the most common endocrinopathy associated with hepatitis C and its interferon-based treatment. When undergoing treatment, interferon and ribavirin synergize to potently stimulate the immune system in order to eradicate the virus. One of the innocent bystanders in this accentuated response is the thyroid. The present study investigated whether thyroid dysfunction while undergoing combination treatment for hepatitis C is a favorable prognostic maker for a sustained virological response.
METHODS: We carried out a prospective clinical audit in 201 patients treated with combination ribavirin and alpha-interferon and determined the prevalence of sustained virological response in patients in association with thyroid disease. A meta-analysis was also carried out pooling 741 patients from four previous studies on this topic.
RESULTS: There was positive and significant association between thyroid disease and viral clearance. This was not supported by the meta-analysis, however, and some plausible explanations are proffered for this inconsistency.
CONCLUSION: Despite lacking supportive evidence from the meta-analysis, it is important that this information is confirmed (or refuted) in future studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682190     DOI: 10.1111/j.1440-1746.2009.05874.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

1.  Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.

Authors:  Jee-Fu Huang; Chao-Kuan Huang; Ming-Lung Yu; Chia-Yen Dai; Chung-Feng Huang; Wei-Wen Hung; Ming-Lun Yeh; Meng-Hsuan Hsieh; Jeng-Fu Yang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Chern Chen; Shun-Sheng Wu; Wan-Long Chuang
Journal:  Hepatol Int       Date:  2011-08-18       Impact factor: 6.047

Review 2.  Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Authors:  Gabriele Pozzato; Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Francesca Zorat; Giulia Moratelli; Pietro Bulian; Diego Serraino; Valter Gattei
Journal:  World J Hepatol       Date:  2016-01-18

3.  Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C.

Authors:  Jennifer S Mammen; Sharon R Ghazarian; Antony Rosen; Paul W Ladenson
Journal:  Thyroid       Date:  2013-08-03       Impact factor: 6.568

4.  Association of interferon-alpha and ribavirin-induced thyroid dysfunction with severity of disease and response to treatment in pakistani asian patients of chronic hepatitis C.

Authors:  Amina Nadeem; Muhammad Aslam
Journal:  Hepat Res Treat       Date:  2012-09-02

5.  Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study.

Authors:  Huy A Tran; Tracey L Jones; Robert Gibson; Glenn Em Reeves
Journal:  BMC Endocr Disord       Date:  2011-05-24       Impact factor: 2.763

6.  Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C.

Authors:  Amina Nadeem; Muhammad Mazhar Hussain; Muhammad Aslam; Tassawar Hussain
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

Review 7.  Relationship between hypothyroidism and periodontitis: A scoping review.

Authors:  Hajer A Aldulaijan; Robert E Cohen; Elizabeth M Stellrecht; Michael J Levine; Lisa M Yerke
Journal:  Clin Exp Dent Res       Date:  2019-09-26

8.  A systematic review and meta-analysis of endocrine-related adverse events associated with interferon.

Authors:  Linghuan Wang; Binqi Li; He Zhao; Peixin Wu; Qingzhen Wu; Kang Chen; Yiming Mu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

Review 9.  Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis.

Authors:  Chandrasekharan Nair Kesavachandran; Frank Haamann; Albert Nienhaus
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

10.  Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.

Authors:  Yong Hwang; Won Kim; So Young Kwon; Hyung Min Yu; Jeong Han Kim; Won Hyeok Choe
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.